Avantor, a provider of products and services for the life sciences industries, has completed a previously announced acquisition of the Masterflex bioprocessing business and related assets of Antylia Scientific, a privately held company.
"The acquisition of Masterflex extends Avantor's single-use offering and gives us a complete end-to-end solution for aseptic fluid transfer throughout the bioproduction workflow," said Michael Stubblefield, President and CEO of Avantor.
"The acquisition demonstrates our commitment to the growing biopharma market and to providing more comprehensive solutions to some of the world's most complex challenges in therapy and vaccine development. We welcome Masterflex associates to the Avantor team and look forward to working together."
Based in Illinois, Masterflex manufactures of peristaltic pumps and aseptic single-use fluid transfer technologies. The acquisition is hoped to strengthen Avantor's offering across all bioproduction platforms including mAbs, cell and gene therapy and mRNA, and supports both therapy and vaccine manufacturing including COVID-19.
